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Increased arteriolar tone is the pathophysiological hallmark of essential hypertension and is determined by the
intracellular free calcium concentration in the vascular smooth muscle cell. Calcium influx is an important
determinant of vasoconstriction and excess calcium influx-dependent vasoconstriction has been shown by
plethysmographical studies in patients with essential hypertension.
Calcium antagonists acutely lower BP by reducing calcium influx, calcium concentration and peripheral
resistance. The degree of the attendant sympathetic nerve reflex activation and counter-regulatory mechanisms
determines the antihypertensive response of the individual. Chronic monotherapy with a calcium antagonist
results in an antihypertensive response, which is directly related to the patient's age and pretreatment BP and
indirectly related to plasma renin levels. The resulting reduction in after-load neither leads to reduced cerebral
blood flow in hypertensive patients, nor aggravates congestive heart failure.
Calcium antagonists are a useful alternative to diuretics, primarily in older patients with low renin levels, either
alone or combined with any other antihypertensive drug, and provide effective and safe control of blood
pressure.
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contraction. The intracellular free calcium concen-
tration has a pivotal role in determining vasoconstric-
tion as the bridging between actin and myosin Platelet calcium-linked abnormalities
depends on the free intracellular calcium ion concen- j n essential hypertension
tration'1-25'. Factors that increase cytosolic calcium
cause vasoconstriction and increase vascular tone, Platelets have been used to study calcium-
whereas factors that lower it cause vasodilation. The dependent processes in patients with essential hyper-
sources of cytosolic calcium may be either extracellu- tension. Platelets have the advantage of clinical
lar, that is, provided by calcium influx, or intracellu- accessibility and cellular homogeneity and might pro-
lar, from storage sites'5-7'. Reduction of the free v i d e a m o d e l f o r vascular smooth muscle through a
calcium concentration results from the action of an n u m b e r of common morphological and functional
features'8'. These include:
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and vasopressin, and alpha2 adrenoceptors, the latter
being linked to an adenylate cyclase system which,
when inhibited, results in vasodilation of smooth
muscle and inhibition of platelet activation'9"10';
(2) the possession of a calcium-dependent contrac-
tile protein coupling system'1112';
(3) the intimate relationship between the physio-
logical changes of platelets and those of smooth
muscle; for example, the release of thromboxane by
platelets leads to vasoconstriction, whereas the
release of prostacyclin by smooth muscle inhibits
platelet activation'1314'.
An elevated free calcium concentration in platelets
from patients with essential hypertension has been
demonstrated in a number of studies, as summarized
in Table 1. Figure 1 shows the correlation between
the intracellular free calcium concentration and sys-
tolic and diastolic blood pressure (BP). Following
antihypertensive therapy with calcium antagonists,
beta-blockers or diuretics, the elevated free calcium
concentration can be normalized'15-20', but an
increased sensitivity to adrenaline which triggers a
rise in free calcium by other hormones remains unal-
tered'21'. Increased calcium influx, as well as blunted
extrusion mechanisms due to altered calcium-
ATPase activity occur'22-23' and may contribute to the
elevated free calcium concentration in the platelets of
patients with essential hypertension.
The complex pattern of altered platelet function in
patients with essential hypertension suggests a causa-
tive underlying membrane pathology. In support of
this hypothesis is the recent demonstration of an
altered interconversion equilibrium of the phospho-
inositides directed towards polyphosphoinositide
formation and, therefore, to enhanced intracellular
calcium release'22'.
Several vasodilators, and calcium antagonists in
general, are inhibitory to platelet activation both in
vitro and in v/Vo'24-25'. This, together with the altered
platelet function of patients with essential hyperten-
sion, points to an altered calcium handling of hyper-
tensive platelets. Although the calcium channel is
genetically one of the oldest cellular membrane
structures in eukaryocytes'26', its long-lasting
development could result in different characteristics
in various cell types. Therefore, using the platelet as a
model for the investigation of altered calcium influx
in essential hypertension could have some limita-
tions; whether the above-mentioned cellular modifi-
cations and possible membrane abnormalities also
apply to smooth muscle cells has yet to be
determined.
Enhanced calcium influx-dependent vasoconstriction
in esssential hypertension
Direct measurements of the function of vascular
smooth cells in hypertension are needed. For this
purpose we used venous occlusion plethysmography
and intra-arterial blood pressure recording to moni-
tor forearm blood flow and vascular resistance'27'.
To determine if enhanced slow channel calcium
influx-dependent vasoconstriction forms part of the
pathophysiological mechanism in essential hyperten-
sion, the vasodilatory response of the regional vascu-
lar bed of the forearm to calcium antagonists was
compared to alpha-1 and alpha-2 adrenoceptor
blocking drugs as well as vasodilator probes which do
not seem to involve slow channel calcium influx, for
example, nitrates. A dose-dependent and enhanced
calcium influx antagonistic vasodilator response was
found in hypertensive patients for different calcium
antagonists, such as for the dihydropyridine calcium
antagonists, nifedipine, nitrendipine and nicard-
ipine, as well as for the non-dihydropyridine calcium
antagonist, verapamil'28' in agreement with those
found by Robinson et al}21\ The magnitude of vaso-
dilation by the different calcium antagonists was
comparable when applied at a maximal locally
effective concentration avoiding systemic effects'28'.
Comparison with other compounds showed that cal-
cium influx-dependent vasodilation following cal-
cium antagonists is similar to the vasodilatory
response to post-ischaemic reperfusion and is about
four times greater than that occurring in response to
alpha-1 or alpha-2 blockade, and three times greater
than the response to sodium nitroprusside'29'. There
are a number of reports that calcium antagonists act
by calcium influx inhibition as well as by interactions
with the calcium pool and calcium extrusion from the
cell'1-3"5-7'. Whatever the molecular basis for
enhanced slow channel calcium influx, the data of
forearm vasodilation show that enhanced calcium
influx is a key contributing factor for the develop-
ment of vascular hypertension responsiveness.
Counter-regulation co-determines the
antihypertensive response
Administration of a calcium antagonist reduces
elevated BP by:
(1) reducing excess calcium-influx dependent vaso-
constriction;
(2) reflexly increasing baroreflex-mediated sym-
pathetic nerve activity as shown by the transient rise
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Table 1 Details of studies which have demonstrated an elevated free calcium concentration in the platelets of patients with
essential hypertension
Study Blood pressure Intracellular calcium (nM) Comments
Normotensives Hypertensives Normotensives Hypertensives
Bruschi et al.il6>
124/79 170/108 108 (N = 30) 168 (W = 23) P < 001
176/114 127 (N = 16) 145 (N = 1 6 ) P < 005
LeQuanSang«a / . 1 1 7 1 94 (mean BP) 129 (mean BP) 202 (N = 27) 254 (W = 34) P < 0 0 1 , after
re-exposure to
extracellular calcium
Lechi et a/.l'8 '
Ashley et alV9]
Erne et al.
(this study)
121 (N = 12) 136 (N =12) P < 005
120/76 179/108
Correlation between
calcium and diastolic
BP : r = 0-55,
P < 005 (N = 16)
Correlation between
calcium and diastolic
BP : r = 0-83, P < 001
(N = 273, including
borderline hypertensives)
in plasma noradrenaline and plasma renin activity
which occurs acutely, but not chronically, with nife-
dipine'30'.
Verapamil and diltiazem have a similar effect on
sympathetic nerve activity, but the effect is less than
that of the dihydropyridine calcium antagonists'31 32'.
When the baroreflex is less active, as is commonly
seen in older patients'32', calcium antagonists pro-
duce a greater fall in BP'30'. These results suggest that
the underlying cardiovascular counter-regulation of
the individual patient co-determines the BP reduc-
tion, and is consistent with the observed reduction in
baroreflex sensitivity and the blunted beta-
adrenoceptor mediated cardiac and renal responses
in older patients and patients with more severe
hypertension'34'. Therefore, in these situations larger
reductions in BP can be expected for the same degree
of vasodilation.
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Figure 1 Correlation between intracellular free calcium concentration in human platelets and systolic
(SBP) and diastolic (DBP) blood pressure. SBP: r = 0-847, DBP: r = 0-836; P < 0001, N = 273, for both.
Intracellular free calcium concentration was determined with the use of quin-2 as described elsewhere11S|.
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Figure 2 Increase in forearm blood flow (AFAF) in
response during reperfusion following 10 minutes of fore-
arm ischaemia and to an intra-arterial (brachial artery)
infusion of sodium nitroprusside, verapamil, nicardipine or
nitrendipine in 10 hypertensive (S) and 10 normotensive
(D) subjects of comparable age and sex. *P < 001.
Antihypertensive treatment concept
with calcium antagonists
The pathophysiological mechanisms considered so
far have been tested in several antihypertensive
treatment studies with different types of calcium
antagonist. The antihypertensive response has been
found to be directly related to patient age and pre-
treatment BP and indirectly related to plasma renin
activity (Fig. 3) |35J61.
The age related efficacy of calcium antagonists is
reciprocal to both that of beta-andrenoceptor-
blocking agents and angiotensin converting enzyme
inhibitors137381. Thus, the diastolic BP of patients
more than 60 years of age normalizes (i.e. < 95 mm
Hg, Korotkoff V) in almost 4 times as many patients
treated with a calcium antagonist than patients
treated with a beta-blocker (Fig. 4), whereas the BP
of patients less than 40 years of age normalizes in
almost 4 times as many patients treated with beta-
blocker monotherapy. Even in the 40-60 year age
group, an age trend emerges. A multivariate analysis
has shown that 36% of the BP reduction can be
accounted for by the age relationship, 31 % by plasma
renin activity and the remaining 33% by the pretreat-
ment BP which is, to some extent, statistically linked
to the drug-induced fall in BP'39'.
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Figure 3 Changes of mean blood pressure (MBP) pro-
duced by calcium antagonist monotherapy were directly
related to (a) patient age. (b) pretreatment blood pressure,
and indirectly related to (c) pretreatment plasma renin
activity (PRA).
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Figure 4 Patient age and response to antihypertensive
monotherapy with (a) a beta-blocker. n = 243: (b) a calcium
antagonist, n = 141.
Comparison of calcium antagonists
ANTIHYPERTENSIVE EFFICACY
Double-blind and open studies have found compa-
rable antihypertensive effects with different calcium
antagonists'164"1. In addition, the antihypertensive
response pattern does not appear to be exclusive to a
particular type of calcium antagonist, for in intra-
individual comparisons of different calcium antago-
nists, including verapamil. diltiazem. nitrendipine
and another 1.4-dihydropyridine. PN 2M. similar
antihypertensive responses were found. From the
current evidence it appears that all available calcium
antagonists have comparable antihypertensive effi-
cacy in patients with mild to moderate hypertension.
Since calcium antagonists seem to act at different
sites, further studies are needed to determine
whether hypertension that is resistant to one calcium
antagonist would respond to a different one, as sug-
gested by a study comparing the effects of verapamil
and nifedipine'41'. Until such data are available, the
choice of drug for antihypertensive therapy is deter-
mined by the side-effects.
SIDE-EFFECTS
Major side-effects can be predicted from the phar-
macological actions of the drug.
(1) Of the calcium antagonists, nifedipine is one of
the most potent vasodilators and so side-effects attri-
butable to vasodilatation, such as headache, flushing
and oedema, are more common with nifedipine than
with verapamil or diltiazem'36*2'.
(2) All calcium antagonists have a negative inotropic
effect in vitro, but this effect is minor in patients with
normal cardiac function'6'.
(3) Verapamil and diltiazem have significant effects
on cardiac conduction'61. Although in most cases
prolongation of atrioventricular conduction time is
asymptomatic'43', clinically significant disturbances
have been reported, including higher forms of
atrioventricular block'44'. Thus, if combinations of
calcium antagonists and beta-blockers have to be
used, a dihydropyridine type is the calcium antago-
nist of choice.
(4) Verapamil has the largest effect on the gastroin-
testinal tract; therefore, constipation is more com-
mon with verapamil than with diltiazem or
nifedipine!1"-45'.
The slightly different patterns of side-effects of
calcium antagonists can determine the calcium
antagonist used for combination therapy. Although
verapamil has been safely combined with beta-
blockers to treat patients with ischaemic heart dis-
ease and there are few cardiodepressant effects when
they are combined in patients with normal cardiac
function'46'47', caution must be observed in patients
taking verapamil or diltiazem with beta-blockers. On
the other hand, nisoldipine and nifedipine have no
apparent negative effect on myocardial contractility
or atrioventricular conduction in vivo in therapeutic
doses, and the current literature indicates that they
can be safely combined with beta-blockers and other
adrenergic inhibitors'4*1'. With respect to the need for
combination therapy, antihypertensive response and
tolerability. there is a great potential for the combin-
ation of calcium antagonists with angiotensin conver-
ting enzyme inhibitors'49'. Combinations of different
calcium antagonists should be considered with
caution because of their different binding structure at
the same calcium channel'5"' which means that the
combined inhibitory effects on calcium influx cannot,
therefore, be preducted safely'51' until there are
reports of controlled studies.
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Effects of calcium antagonists on coronary and
cerebral blood flow
Clinical studies have demonstrated the antihyper-
tensive efficacy of calcium antagonists in elderly
hypertensive subjects. Calcium antagonists cause
widespread arterial and arteriolar vasodilatation, but
they vary in their ability to dilate different vascular
beds. With respect to the safety of this therapy,
therefore, special attention must be given to the
effects of calcium antagonists on coronary and cere-
bral blood flow.
CORONARY BLOOD FLOW
The effects of the calcium antagonist, nisoldipine,
were investigated in 18 patients with congestive heart
failure which was resistant to basic therapy, acutely
and for 4 weeks after therapy. Both stroke volume
and ejection fraction increased acutely, during exer-
cise and chronically. The change in systemic vascular
resistance correlated with the change in stroke
volume. Following acute administration of nisoldi-
pine in a subset of these patients, coronary blood flow
determined by continuous thermodilution'52'
increased by 25%, at rest and during exercise'48'.
CEREBRAL BLOOD FLOW
The cerebral blood flow is usually maintained
within narrow limits over a wide range of BP'53'. In
essential hypertension, this autoregulation of cere-
bral blood flow is adapted to the height of the BP and
this explains the possible cerebral deterioration dur-
ing rapid and rigorous normalization of BP by anti-
hypertensive treatment. While investigation of the
acute effects of nifedipine in humans, or after short-
term therapy with nimodipine in an animal study,
showed an increase of cerebral blood flow'54-55', no
change of cerebral blood flow was found in 10
patients with essential hypertension (age 50-67
years) following treatment with nitrendipine for 4
weeks (BP before nitrendipine, 165 ± 16/106 + 5 w
144 ± 12/88 ±7mmHg on nitrendipine; P< 0-001;
cerebral blood flow before nitridipine 51-5 ±1 vs 50-8
±7-8 ml 100g~' min"1 on nitrendipine; an insignifi-
cant difference'56'. These differences between acute
or short term, and long-term effects are probably due
to an increase of cerebral blood flow induced by
activation of sympathetic activity and enhanced bar-
oreflex sensitivity following the acute administration
of calcium antagonists'30'.
Conclusion
These results suggest that calcium antagonists can
be administered safely under controlled conditions to
elderly patients with or without congestive heart
failure'57"59'. The contrasting pattern of antihyperten-
sive efficacy observed with beta-blockers and
angiotensin converting enzyme inhibitors on the one
hand, and calcium antagonists and diuretics on the
other, suggests that:
(1) the initial treatment for younger patients with
high plasma renin activity might be a beta-blocker or
a converting enzyme inhibitor;
(2) the initial treatment for older patients with low
plasma renin activity might be a calcium antagonist or
a diuretic;
(3) a beta-blocker or a calcium antagonist may be
used as the initial treatment for patients of 40-60
years of age and for patients with a normal plasma
renin activity.
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